

# Global Oncology Preclinical Drug Intelligence 2022 - World's Largest Active Resource for Decision Making

*First Report to provide Extensive Insights on 1200+ Active Early Stage Oncology Companies developing over 1400+ New Drug Molecules Targeting Cancer*


NEW DELHI, DELHI, INDIA, July 12, 2022

[/EINPresswire.com/](https://www.einpresswire.com/) -- As per [OmicsX](https://www.omicsx.com/) records, each year globally approximately 400 new oncology targeting companies are established with new ideas to develop new molecules against cancer. Due to the large number and global distribution, it is quite difficult for market analysts and business development professionals to identify the growing number of active drug developers and track their technologies and business activities on routine basis.



Specially designed to identify early stage researchers with new ideas capable of changing the face of drug discovery."

*Amit Gupta - Editor*



Global Distribution of 1200 Active Early Stage Drug Developers Covered inside Report

[Global Oncology Preclinical Stage Drug Intelligence Report 2022](#), covers largest set of authentic early stage oncology drug developers worldwide with their technology and early stage molecules available for partnering and is a perfect tool to identify new partnering leads.

Report for the first time identifies and profiles 1200 Active Early Stage Cancer Drug Development companies from 33 countries worldwide, developing 1400+ cancer-targeting

drugs. It evaluates individual company's technology, cancer indications drug development pipeline & analysis, drug targets information, Key Management Social and Business Contacts details and thus creates immense authentic knowledge base on hundreds of emerging proprietary technologies, M&A deals and partnering occurring in early stage cancer drug

discovery domain in recent years.

## KEY HIGHLIGHTS -

Report covers Entrepreneurs established in last few years with valid funding and clear demarked pipeline with Individual's Technology, Pipeline, Drug Targets, Management, Funding and Partnering capabilities.

Complete Insights on Single Platform - Drug Developers, Emerging Technologies, Molecules, Targets, Mechanism of Action, Partnering Activities, Key Managements Social and Business Contacts.

Best Selling Product since more than a decade, and is developed through years of continues & dedicated team work.

Economic & User Friendly Option in compare with any other similar available market solution.

Report comes with Complete Free after sales Support and Further Report Customization Options with regular intelligence updates for next one year.

## INSIDE REPORT -

Complete Prebuild Intelligence (All in Single Report)

Small Molecule : Kinase Inhibitors (122 Preclinical Stage Companies).

Small Molecule : Proteolysis Targeting Chimera (PROTACs) (29 Preclinical Stage Companies).


Small Molecule : RNA Targeting Therapeutics (43 Preclinical Stage Companies).

Nanoparticles / Nanotechnology based Cancer Targeting Drugs (61 Preclinical Stage Companies).

Cellular Therapy: T Cell/CAR-T/CAR-NK & other Cell based Therapies (125 Preclinical Stage Companies).

Oncolytic Viruses Pipeline in Early Stage Development (35 Preclinical Stage Companies).

Monoclonal Antibodies Pipeline in Early Stage Development. (162 Preclinical Stage Companies)



Oncology Preclinical Stage Drug Developers Present in Europe, Asia and United States

**11<sup>TH</sup> UPDATED EDITION**

# GLOBAL ONCOLOGY PRECLINICAL DRUG INTELLIGENCE

Technologies @ Pipeline @ Companies @ Deals

**FIRST INTELLIGENCE TO COVER 1200+ ACTIVE ONCOLOGY PRECLINICAL STAGE DRUG DEVELOPERS**

RELEASED IN MAY 2022

**WORLD'S LARGEST RESOURCE FOR DECISION MAKING**

Global Oncology Early Stage Drug Intelligence Report 2022

Bi-Specific & Multi Specific Antibodies pipeline in Early Stage Development (66 Preclinical Stage Companies).

Antibody Drug Conjugates Pipeline in Early Stage Development (62 Preclinical Stage Companies).

Cancer Vaccines Pipeline in Early Stage Development (80 Preclinical Stage Companies)

Exosome & Micro vesicles based Cancer Targeting Drugs (17 Preclinical Stage Companies).

Microbiome based Cancer Targeting Drugs (15 Preclinical Stage Companies).

Largest set of authentic early stage oncology drug developers worldwide with early stage molecules available for partnering and is a perfect tool to identify new partnering leads.

INDEX - Active Preclinical Stage Onco Drug Developers Included in Report (Alphabetically)

1E Therapeutics Ltd.

1st Biotherapeutics Inc.

20n Bio, Inc.

21st Century Therapeutics, Inc.

2A Pharma AB

3T Biosciences

4C Biomed, Inc

858 Therapeutics, Inc

A2 Biotherapeutics, Inc

A2A Pharmaceuticals

A2i Therapeutics Ltd

A6 Pharmaceuticals

Aakha Biologics, Inc

Aarvik Therapeutics, Inc

Aavocyte Inc.

Ab Therapeutics, Inc.

Abalone Bio, Inc.

Abalos Therapeutics

ABBA Therapeutics AG

AbClon Inc.

Abcuro, Inc.

Abera Bioscience AB

Abilita Bio, Inc.

Abintus Bio, Inc.

AbLeads

Abologix Sàrl

Abound Bio, Inc.

Abpro Therapeutics

AbSano B.V.

Absolve Therapeutics, Inc.

AbTis Co, Ltd.

Abzyme Therapeutics, LLC  
AC BioScience SA  
AcadeMab Biomedical Inc.  
Accent Therapeutics  
Accuronix Therapeutics  
Aceragen, Inc.  
Actavalon  
Actinobac Biomed Inc  
ActoKine Therapeutics, Inc.  
Actym Therapeutics  
Adamed Pharma S.A.  
Adanate, Inc.  
Adaptive Biotechnologies Corp.  
ADCendo ApS  
Adcentrx Therapeutics, Inc.  
AdCure Bio LLC  
Adecto Pharmaceuticals, Inc.  
Adendra Therapeutics  
AdoRx Therapeutics

& 1151 more Active Early Stage Drug Developers....  
with 1400+ Early Stage Active Molecules, Target, Tech. Deals and management contact details.

REPORT PROVIDES LARGEST COVERAGE - GURANTEED

Further Details & Download Preview Copy :- <https://omicsx.com/reports/cancer/global-oncology-preclinical-drug-intelligence-2022/>

For Social Newsletter based on this Report - <https://www.linkedin.com/newsletters/oncology-drug-developers-6937698358589288449/>

Virendra Singhvi  
OmicsX  
+91 97602 41412  
info@omicsx.com

---

This press release can be viewed online at: <https://www.einpresswire.com/article/580916798>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2022 Newsmatics Inc. All Right Reserved.